NASDAQ: CAPRCapricor Therapeutics Inc Stock
$18.91-0.88 (-4.45%)
Updated Jul 22, 2026
CAPR Price
$18.91
Fair Value Price
$5.81
Market Cap
$1.10B
52 Week Low
$4.30
52 Week High
$40.37
P/E
-8.15x
P/B
3.93x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$114.59M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.17
Operating Cash Flow
-$93M
Beta
1.06
Next Earnings
Aug 10, 2026
Ex-Dividend
N/A
Next Dividend
N/A
CAPR Overview
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CAPR's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -12.86% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CAPR
Ranked#410 of 464
Ranked#410 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $250.41 | A | |
| $11.13 | A | |
| $8.38 | A |
Be the first to know about important CAPR news, forecast changes, insider trades & much more!
CAPR News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CAPR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CAPR ($18.91) is overvalued by 225.64% relative to our estimate of its Fair Value price of $5.81 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CAPR ($18.91) is not significantly undervalued (225.64%) relative to our estimate of its Fair Value price of $5.81 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CAPR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CAPR due diligence checks available for Premium users.
Valuation
CAPR fair value
Fair Value of CAPR stock based on Discounted Cash Flow (DCF)
Price
$18.91
Fair Value
$5.81
Overvalued by
225.64%
CAPR ($18.91) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CAPR ($18.91) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CAPR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CAPR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-8.15x
Industry
21.5x
Market
12.86x
CAPR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.93x
Industry
5.34x
CAPR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CAPR's financial health
Profit margin
Revenue
$0.0
Net Income
-$33.9M
Profit Margin
0%
CAPR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$326.3M
Liabilities
$47.6M
Debt to equity
0.17
CAPR's short-term assets ($283.09M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CAPR's short-term assets ($283.09M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CAPR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CAPR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$29.3M
Investing
-$154.6M
Financing
$1.5M
CAPR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CAPR vs Biotech Stocks
Capricor Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.